PF-Atlas › Clinical Trials › NCT00782288

Phase II Study of Digitoxin to Treat Cystic Fibrosis

digitoxin · Phase 2

Registry ID

NCT00782288

Phase

Phase 2

Status

Completed

Drug / intervention

digitoxin

Sponsor

National Jewish Health

Start

2010-08

Enrollment

Locations

About this trial

This study will measure the inflammatory effects of digitoxin on IL-8 and neutrophil counts in induced sputum in stable Cystic Fibrosis (CF) patients and the pharmacokinetics of digitoxin in serum. Funding Source-FDA OOPD

View NCT00782288 on ClinicalTrials.gov →

Explore related

All digitoxin trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT00782288 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.